Stemline Therapeutics, Inc.

Organization

Ivan Bergstein, M.D. Chief Executive Officer	Dr. Bergstein has served as Stemline's CEO since its inception in 2003. Formerly, Dr. Bergstein was Medical Director of Access Oncology, Inc., a private clinical stage oncology-focused biotechnology company, where he was a key member of the founding team that built the company's clinical pipeline and ultimately transitioned the company into its acquirer, Keryx Biopharmaceuticals (Nasdaq: KERX). Prior to this, he was senior biopharmaceuticals analyst at a Wall Street-based firm, Cancer Advisors Inc., which advised investment funds on public oncology-focused companies. He received a B.A. in mathematics from the University of Pennsylvania and an M.D. from the Mount Sinai Medical Center where he completed a general surgery internship. Subsequently, he was named the Jerome A. Urban post-doctoral fellow at Cornell University Medical College. Dr. Bergstein then went on to complete a residency in internal medicine and clinical fellowship in hematology-medical oncology at the New York Presbyterian Hospital-Weill Medical College of Cornell University where he is currently a voluntary faculty member.

Eric Rowinsky, M.D. Chief Medical Officer, Head of Research and Development	Dr. Rowinsky has more than 25 years of experience managing clinical trials and developing drugs from preclinical to regulatory approval. He was Executive Vice President and Chief Medical Officer for Imclone Systems, Inc., where he led the FDA approval of Erbitux^® for head and neck and colorectal cancer, and advanced eight other monoclonal antibodies through clinical development. Dr. Rowinsky was Director of the Institute of Drug Development ("IDD") at the Cancer Therapy and Research Center. In addition, he held the SBC Endowed Chair for Early Drug Development at the IDD and was a Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins University School of Medicine. He was a longstanding NCI principal investigator on U01 anticancer drug development grants, and was integrally involved in pivotal clinical and preclinical investigations, which led to the development of paclitaxel, docetaxel, topotecan, irinotecan, erlotinib, gefitinib, and temsirolimus, among others. Dr. Rowinsky is currently an Adjunct Professor of Medicine at New York University School of Medicine and sits on the Board of Directors of a number of public and private biopharmaceutical companies, including Biogen Idec, Inc. Dr. Rowinsky received his M.D. from Vanderbilt University School of Medicine. He completed his residency in internal medicine at the University of California, San Diego and his fellowship in medical oncology at Johns Hopkins Oncology Center.

Thomas P. Cirrito, Ph.D. Director of Operations	Prior to joining Stemline, Dr. Cirrito was a biopharmaceuticals equities analyst at Piper Jaffray, where he covered large and small cap biotechnology companies. Previously he was a life sciences consultant for A.G. Edwards Capital Partners, a venture capital group . He received a B.A. in Biological Sciences and a Ph.D. in Immunology from Washington University (St. Louis, MO). Dr. Cirrito currently serves on the Scientific and Business Advisory Board of the Alzheimer's Drug Discovery Foundation.

Michael Szarek, Ph.D. Clinical and Regulatory Affairs	Dr. Szarek has over 15 years of experience in clinical and regulatory affairs in multiple therapeutic areas. He previously led a regulatory affairs team at ImClone Systems, Inc. that was responsible for development strategies for Erbitux^® (cetuximab) and multiple other monoclonal antibody therapeutics. Prior to ImClone, he was a director and biotechnology analyst and CIBC World Markets (later Oppenheimer and Co.). Previously, he was the worldwide statistical lead for Lipitor^® (atorvastatin) at Pfizer, Inc. Dr. Szarek has published over 30 articles in leading medical and statistical journals and has served on numerous independent academic Steering Committees and Data Monitoring Committees for Phase 3 trials. He earned a MS degree in biostatistics from Harvard School of Public Health, and a PhD in biostatistics from New York University.

Joan Shankle Regulatory Affairs	Ms. Joan Shankle has over 30 years of experience in the biopharmaceutical industry. Ms Shankle specializes in quality and regulatory development and has filed multiple BLAs and NDAs. She has led teams involved in oncology drug development, including Ontak^® (denileukin diftitox). Most recently, Ms. Shankle led the regulatory program for Istotax^® (romidepsin) at Gloucester Pharmaceuticals, leading to FDA approval, and the acquisition of Gloucester by Celgene.

John O’Loughlin, Ph.D. Chemistry, Manufacturing, and Controls (CMC)	Dr. O’Loughlin has over 27 years of experience with biopharmaceuticals chemistry, manufacturing, and controls (CMC). He has held senior positions at Seragen Inc., Imreg Inc. and Interferon Sciences. Earlier in his career, Dr. O’Loughlin led the process development and manufacturing of Ontak^® at Marathon Biopharmaceuticals, the first dedicated contract manufacturer approved for the commercial production of a recombinant biologic. As an executive consultant he has also worked on process/product development, analytical biochemistry, CMC and regulatory strategy with multiple companies including Ligand Pharmaceuticals, Cambrex Inc., Adnexus Therapeutics, and GTC Biotherapeutics.

Robert Niecestro, Ph.D. Regulatory	Dr. Niecestro has over 25 years of experience in managing clinical and regulatory development. He has held senior positions at Andrx Corp., Eisai Pharmaceuticals, and Organon Biosciences. Dr. Niecestro has filed over 30 INDs and multiple NDAs including Aciphex^®, Orgaran^®, metformin-ER, and lovastatin-ER.

John Dillberger, Ph.D. Pharmacology and Toxicology	Dr. Dillberger has over 22 years experience in the pharmaceutical industry. He has served as Head of USA Pathology, Director of Safety Evaluation for USA-Based Development Projects, and Worldwide Specialist in Oncology Drug Projects for GlaxoWellcome and as Director of Toxicology at Triangle Pharmaceuticals. Dr. Dillberger has prepared safety evaluation packages for numerous clinical trial and marketing applications in the USA and Europe.

Chris Brooks, Ph.D. Associate Director, R&D	Prior to joining Stemline, Dr. Brooks was a senior staff scientist at Progenics Pharmaceuticals, Inc., where he led an R&D team that developed novel antibody therapeutics. He has published numerous papers, including peer-reviewed articles and book chapters, on molecular mechanisms of cancer development. His research has been featured in journals such as Science, Current Opinions in Cell Biology, Cancer Cell, and Nature Reviews Cancer. He received a B.S. in Biological Sciences cum laude from Binghamton University and an M.A., M.Phil., and Ph.D. in Pathology and Cell Biology from the College of Physicians and Surgeons at Columbia University.

Mark Jacobson, M.A. Associate Director, Business Development	Mark Jacobson joined Stemline Therapeutics in July 2009. Previously, he worked as a healthcare analyst for Publicis Healthcare Communications Group, a life sciences marketing and communications company, where he developed research reports on the healthcare industry as a whole and on targeted companies within the industry. Mr. Jacobson received a B.S. in biology with honors from Iowa State University and obtained a Master’s degree in Biotechnology from Columbia University.